Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort
Nikolas Plevris, Charlie W. Lees(University of Edinburgh), Eliana Saffouri(Glasgow Royal Infirmary), Graham Naismith(Royal Alexandra Hospital), Wai Liam Lam(Glasgow Royal Infirmary), Daniel R. Gaya(Glasgow Royal Infirmary), Arjun Sengupta(Victoria Hospital), Paul Brennan(Ninewells Hospital), P Shasi(Ninewells Hospital), Gareth‐Rhys Jones(MRC Centre for Regenerative Medicine), Shahida Din(Western General Hospital), M MacMaster(Glasgow Royal Infirmary), Angus Watson(Raigmore Hospital), Hasnain Jafferbhoy(Victoria Hospital), Sardar Chaudhary(Hairmyres Hospital), Craig Mowat(Ninewells Hospital), Philip Jenkinson(Western General Hospital), Lindsay Potts(Raigmore Hospital), Rhiannon Allen(Glasgow Royal Infirmary), Diarmid Sutherland(Hairmyres Hospital), Ian Arnott(Western General Hospital), David Watts(Forth Valley Royal Hospital), Jonathan Macdonald(Queen Elizabeth University Hospital), Jennifer Veryan(Glasgow Royal Infirmary), Cher Shiong Chuah(Western General Hospital), Emma Donoghue(Forth Valley Royal Hospital), A. M. D. Churchhouse(Victoria Hospital), Mathew Lyons(Western General Hospital), John Paul Seenan(Queen Elizabeth University Hospital), M Groome(Ninewells Hospital), John A. Todd(University of Cambridge)
Cited by 51
Related Papers
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
|Nature|2007|9.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease
|Nature Genetics|2017|1.5k
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes
|Nature Genetics|2007|1.5k